Biotech is back in Germany Latham & Watkins and Hengeler Mueller advised on Germany's first initial public offering for a biotech company since 2001 and only the fourth IPO in the country this year. Latham advised the company, Epigenomics, on the €41.6 million deal. Hengeler Mueller acted for lead manager Morgan Stanley.
July 31 2004